![]() Just enter your target sequences and the software determines primer designs for the most complete DNA coverage. The methylated and non-methylated cytosine residues in the original genomic DNA are easily distinguished using EpiTYPER Software.ĮpiDesigner is an online automated design tool for DNA methylation experiments on the MassARRAY System. Finally, the cleavage products are analyzed using MALDI-TOF mass spectrometry (MassARRAY Analyzer). Next, in vitro RNA transcription is performed, followed by base-specific RNA cleavage. The reverse primers contain a T7 promoter tag. ![]() It is particularly suitable for larger scale efforts to study candidate regions or to validate regions from genome-wide DNA methylation studies.ĮpiTYPER biochemistry starts with bisulfite treatment of genomic DNA, followed by PCR amplification of target regions. The technology interrogates 10s-100s of samples and CpG sites in amplicons from 200 - 600 bp and detects down to 5% differences in methylation. EpiTYPER is a MALDI-TOF mass spectrometry-based bisulfite sequencing method that enables region-specific DNA methylation analysis in a quantitative and high-throughput fashion. The DNA methylation analysis technology, EpiTYPER MassARRAY, provided by Agena Bioscience (previously Sequenom Inc.), is one of the most reliable quantitative methods available today for DNA methylation analysis. Gene Expression Profiling Microarray Service.MicroRNA Expression Profiling Microarray Service.Single-cell RNA Sequencing Data Analysis Service.Long-Read Sequencing Data Analysis Service.SNaPshot Multiplex System for SNP Genotyping.Lentiviral/Retroviral Integration Sites Analysis.Antibody Screening Sequencing (Phage Display Library Screening).Nanopore Full-Length Transcripts Sequencing. ![]() Absolute Quantitative 16s/18s/ITS Amplicon Sequencing.Full-Length 16S/18S/ITS Amplicon Sequencing.Human Whole Genome PacBio SMRT Sequencing.Full-Length Transcripts Sequencing (Iso-Seq).Bacterial Whole Genome de novo Sequencing.DAP-Seq Service (DNA affinity purification sequencing).Whole Genome Bisulfite Sequencing (WGBS).Reduced Representation Bisulfite Sequencing.Human Mitochondrial DNA (mtDNA) Sequencing.Comparison of saliva and nasopharyngeal swab nucleic acid amplification testing for detection of SARS‐CoV‐2: a systematic review and meta‐analysis. Accessed February 21, 2021.īutler‐Laporte G, Lawandi A, Schiller I, et al. Diagnostics in the time of coronavirus disease 2019 (COVID‐19): challenges and opportunities. ![]() Laboratories and pandemic preparedness: a framework for collaboration and oversight. Comparison of commercially available and laboratory‐developed assays for in vitro detection of SARS‐CoV‐2 in clinical laboratories. Lieberman JA, Pepper G, Naccache SN, Huang M‐L, Jerome KR, Greninger AL. ![]() MALDI-TOF SARS-CoV-2 real-time RT-PCR saliva. We conclude that the MassARRAY® system is a sensitive and reliable platform for SARS-CoV-2 detection in saliva, offering scalable throughput in a large variety of clinical laboratory settings. Together, we demonstrate that saliva represents an appropriate matrix for SARS-CoV-2 detection on the novel Agena system as well as on a conventional real-time RT-PCR assay. Overall, this system also demonstrated comparable performance when compared to the detection of SARS-CoV-2 RNA in saliva by the cobas® 6800/8800 SARS-CoV-2 real-time RT-PCR Test (Roche). Furthermore, across the five individual target components of this assay, there was a range in analytic sensitivities for each target with the N2 target being the most sensitive. We also evaluated the analytical sensitivity of the platform and determined the limit of detection of the assay to be 1562.5 copies/ml. The platform demonstrated high diagnostic sensitivity and specificity when compared to matched patient upper respiratory specimens. Here, we used a novel sensitive RT-PCR/MALDI-TOF mass spectrometry-based assay (Agena MassARRAY®) to detect SARS-CoV-2 in saliva specimens. While saliva has been described as an acceptable clinical matrix for the detection of SARS-CoV-2, evaluations of analytic performance across platforms for this specimen type are limited. Although multiple diagnostic methods utilize nasopharyngeal specimens, saliva specimens represent an attractive alternative as they can rapidly and safely be collected from different populations. As severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infections continue, there is a substantial need for cost-effective and large-scale testing that utilizes specimens that can be readily collected from both symptomatic and asymptomatic individuals in various community settings. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |